How to buy Sienna Cancer Diagnostics shares

Sienna Cancer Diagnostics Limited is a diagnostics & research business based in Australia. Sienna Cancer Diagnostics shares (SDX) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Sienna Cancer Diagnostics has a trailing 12-month revenue of around $999,521.

How to buy shares in Sienna Cancer Diagnostics

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Sienna Cancer Diagnostics . Find the share by name or ticker symbol: SDX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sienna Cancer Diagnostics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Sienna Cancer Diagnostics . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

Sienna Cancer Diagnostics share price

Use our graph to track the performance of SDX stocks over time.

Sienna Cancer Diagnostics shares at a glance

• Key figures

Information last updated 2020-08-29.

52-week range	AUDA$0.02 - AUDA$0.08
50-day moving average	AUDA$0.0692
200-day moving average	AUDA$0.0519
Target price	AUDA$0.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.011

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Sienna Cancer Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sienna Cancer Diagnostics Limited by TradingView

Sienna Cancer Diagnostics financials

Revenue TTM	$999,521
Gross profit TTM	$989,610
Return on assets TTM	-20.32%
Return on equity TTM	-35.97%
Profit margin	0%
Book value	0.026
Market capitalisation	$27.7 million

TTM: trailing 12 months

Sienna Cancer Diagnostics share dividends

We're not expecting Sienna Cancer Diagnostics to pay a dividend over the next 12 months.

Sienna Cancer Diagnostics share price volatility

Over the last 12 months, Sienna Cancer Diagnostics 's shares have ranged in value from as little as $0.02 up to $0.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Sienna Cancer Diagnostics 's is 3.007. This would suggest that Sienna Cancer Diagnostics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sienna Cancer Diagnostics overview

Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The company offers SCD-A7, an anti-human telomerase reverse transcriptase antibody for the detection of the biomarker for cancer. It also provides SIEN-NET technology, a sample preparation platform to enhance the performance of liquid biopsy diagnostic assays. The company has a research collaboration agreement with Minomic International Ltd to develop a proprietary test for the early detection of pancreatic cancer. The company was formerly known as Sienna Capital Ltd and changed its name to Sienna Cancer Diagnostics Limited in 2006. Sienna Cancer Diagnostics Limited was founded in 2002 and is headquartered in Scoresby, Australia.

Frequently asked questions

• What percentage of Sienna Cancer Diagnostics is owned by insiders or institutions?

  Currently 41.354% of Sienna Cancer Diagnostics shares are held by insiders and 16.065% by institutions.

• When does the fiscal year end for Sienna Cancer Diagnostics ?

  Sienna Cancer Diagnostics 's fiscal year ends in June.

• Where is Sienna Cancer Diagnostics based?

  Sienna Cancer Diagnostics 's address is: Small Technologies Cluster, Scoresby, VIC, Australia, 3179

• What is Sienna Cancer Diagnostics 's ISIN number?

  Sienna Cancer Diagnostics 's international securities identification number is: AU000000SDX1